O’Neil Health Care Weekly

XLV traded relatively flat last week, still holding support along its rising 21-DMA ($145.19). Support below this level is the rising 50-DMA
($142.30). We continue to recommend an equal-weight sector positioning given its RS line remains in a longer-term downtrend and
has yet to make short-term progress. With that said, we believe any sustained pullback in the market will result in relative
improvement in the sector.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq bounced off 21-DMA support (5,055/15,929) mid-week but staged a downside reversal on Friday. However, both indices remain near all-time highs and above 21-DMA support. The distribution day count increased to eight on the Nasdaq and remains at five on the S&P 500 with one day expiring on each index next week.

O’Neil Health Care Weekly

XLV declined 1% last week, but held 21-DMA ($144.64) support Friday. We continue to recommend an equal-weight sector
positioning as its RS line remains in a longer-term downtrend versus the broader market. Within the sector, we continue to
recommend an overweight positioning in Medical Technology and Biotech.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 finished strong and closed the week up 1%, while the Nasdaq gained 1.7%. Neither index has any remaining resistance as the S&P 500 continued further into all-time highs and the Nasdaq surpassed its 2021 peak of 16,212 for the first time. Indices have the first level of support at their 10-DMA (5,059/15,935). Below that, the 21-DMAs are the most major level of support (5,016/15,819). The distribution day count on each index stands at six, with one set to expire in the coming week.

O’Neil Health Care Weekly

XLV gained 1.5%, rallying for a fourth straight week as it trends along support at its 10-DMA ($145.41) and 21-DMA ($143.31). Despite
good absolute performance, we continue to recommend an equal-weight sector positioning as its RS line remains in a longer-term
downtrend versus the broader market.

O’Neil Health Care Weekly

XLV gained 1.1% last week continuing its move into new all-time highs. The 21-DMA ($142.42) has been acting as a solid level of
near-term support since November. The RS line has risen from lows, but has yet to make a higher high, warranting an equal-tounderweight sector positioning, which will likely change should the broader tape come under pressure.

Market View

The U.S. market remains in a Confirmed Uptrend. This week, the S&P 500 fell 0.4% while the Nasdaq fell 1.4%. Both indices bounced from 21-DMA support (4,936/15,582) but closed a bit off the highs established on Monday. The S&P 500 is still well into all-time highs while the Nasdaq is about 2% below its Q4 2021 peak (16,212). Indices are about 4% extended from their 50-DMA (4,813/15,134). The distribution day count stands at five and four, respectively, after each index picked two this week (Tuesday and Friday).

O’Neil Health Care Weekly

XLV gained 1.4% last week, pacing the S&P 500 and breaking into new all-time highs. The 21-DMA ($141.15) has been acting as a solid level of near-term support since November. Despite a steady trend higher, the RS line remains in a longer-term downtrend as Health Care leadership remains narrow and unable to keep up with the Tech heavy rally. We continue to recommend an equal-to underweight sector positioning, which will likely change should the broader tape come under pressure.